| Neurology Office Joseph Kandel Md & Associates, Pllc | |
|
1020 Crosspointe Dr Suite 1 Naples FL 34110-0918 | |
| (239) 552-6335 | |
| Not Available |
| Full Name | Neurology Office Joseph Kandel Md & Associates, Pllc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 1020 Crosspointe Dr, Naples, Florida |
| Authorized Official Name and Position | Joseph Kandel (OWNER) |
| Authorized Official Contact | 2395526335 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Neurology Office Joseph Kandel Md & Associates, Pllc 1020 Crosspointe Dr Suite 1 Naples FL 34110-0918 Ph: (239) 552-6335 | Neurology Office Joseph Kandel Md & Associates, Pllc 1020 Crosspointe Dr Suite 1 Naples FL 34110-0918 Ph: (239) 552-6335 |
| NPI Number | 1851781116 |
|---|---|
| Provider Enumeration Date | 01/26/2015 |
| Last Update Date | 02/26/2021 |
| Certification Date | 02/26/2021 |
| Medicare PECOS PAC ID | 4183945934 |
|---|---|
| Medicare Enrollment ID | O20150604001503 |
News Archive
Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.
With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851781116 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | (* (Not Available)) | Primary |
| Provider Name | Joseph Kandel |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1427057462 PECOS PAC ID: 8224936323 Enrollment ID: I20040115001080 |
News Archive
Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.
With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
› Verified 6 days ago
| Provider Name | Rebecca Sabogal |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205169067 PECOS PAC ID: 4082858113 Enrollment ID: I20130911000618 |
News Archive
Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.
With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
› Verified 6 days ago
| Provider Name | Kelly Keller Ahmad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093148611 PECOS PAC ID: 5597990739 Enrollment ID: I20131024001258 |
News Archive
Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.
With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
› Verified 6 days ago
| Provider Name | Genesis G Flanagan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396107223 PECOS PAC ID: 4880974617 Enrollment ID: I20161213000721 |
News Archive
Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.
With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
› Verified 6 days ago
News Archive
Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.
With guidance from a specialized scan, radiation oncologists at Mayo Clinic were able to reduce by 55 percent the number of lymph nodes critical for removing fluid from the arm that received damaging radiation doses.
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons – the tiny fibers that link our nerve cells and enable them to communicate – to regrow after complete spinal cord injury in rodents. Not only did the axons grow through scars, they could also transmit signals across the damaged tissue.
› Verified 6 days ago
Fresh Start Private Florida Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1415 Panther Ln, Naples, FL 34109 Phone: 239-591-6240 | |
Mindful Solutions Therapy, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4532 Tamiami Trl E Ste 302, Naples, FL 34112 Phone: 239-307-8038 | |
Psychotherapy Sw Fl Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 810 Anchor Rode Dr, Naples, FL 34103 Phone: 239-247-4231 | |
Little World Aba Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 708 Goodlette-frank Rd N Ste 326, Naples, FL 34102 Phone: 239-200-2405 | |
Dnt Institute Incorporated Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1750 Sw Health Pkwy, Naples, FL 34109 Phone: 239-566-7717 | |
Nami Of Collier County Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5020 Tamiami Trl N, Suite 110, Naples, FL 34103 Phone: 239-434-6726 | |
Behavioral Tender Care Corp Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 300 5th Ave S Ste 203d, Naples, FL 34102 Phone: 786-734-0684 |